

Prescription Opioid Use, Injecting Drug Use and HCV in Rural and Suburban Settings

Jennifer R. Havens, PhD, MPH Center on Drug and Alcohol Research









Van Handel et al. JAIDS, 2016

Vulnerable Areas for HIV/HCV





Van Handel et al. JAIDS, 2016





FIGURE 2. Age distribution of newly reported confirmed cases of hepatitis C virus infection — Massachusetts, 2002 and 2009

* N = 6,281; excludes 35 cases with missing age or sex information. † N = 3,904; excludes 346 cases with missing age or sex information.


MMWR, May 6, 2011; 60(17): 537-541



Appalachian "Pain Culture"

- Laborious industries
 - Mining
 - Lumber
- Culture established that pain=opioids long before the recent epidemic
- Pain culture contributed to current epidemic
 - View of safety and legality of sharing





Longitudinal Study to Determine Vulnerabilities to Prescription Opioid Abuse and Associated Harms in Rural Appalachia

- Social Networks among Appalachian People (SNAP) study
- Purpose: determine prevalence and incidence of HCV, HIV and HSV-2 in relation to social network characteristics among rural drug users
- 500 rural out-of-treatment PWID/non-PWID recruited and followed at 6-, 12-, 18-, 24-, 30-, and 36-months postbaseline (95% f/u at 18-months; 91% at 36-months)







- Age 18+
- English-speaking
- PWID (initial seeds)
- Use of at least 1 of the following drugs to get high in prior 30 days:
 - Rx Opiates (illicit use)
 - Cocaine
 - Heroin
 - Methamphetamine



Participant Characteristics N=503

	n	%
Male	286	56.7
Age, median (IQR)	31 (26 ,38)	
Caucasian	474	94.2
Employed Full-Time	173	34.4
Lifetime Injection Drug Use	394	78.3




Recent Drug Use 2008 and 2016

	Past 30 Days 2008	Past 30 Days 2016
Buprenorphine (illicit) ¹	Not queried	19.2%
Methadone (illicit) ²	60.8	7.9
Heroin	4.4	1.4
OxyContin ³	69.8	1.1
Roxicodone	72.4	17.3
Hydrocodone	81.3	23.3
Benzodiazepines	85.3	28.8
Methamphetamine	3.4	4.6
Cocaine	22.5	9.8
Gabapentin ⁴	0	47.7



¹Lofwall and Havens. *Drug and Alcohol Depend*, 2012 ²Hall, Leukefeld, Havens. *Am J Drug Alcohol Abuse*, 2013 ³Jonas, Young, Oser, Leukefeld, Havens. *Soc Sci Med*, 2012 ⁴Smith, Lofwall, Havens. *Am J Psychiatry*, 2015




HIV: Crosby, Oser, Leukefeld, Havens, Young. Annals of Epidemiol, 2012
HCV: Havens, Lofwall, Frost, Oser, Leukefeld, Crosby. Am J Public Health, 2013
HSV2: Stephens, Young, Mullins, Havens. J Med Virology, 2016


Independent Correlates of Seroprevalent HCV Infection

	aOR	95% CI
Syringe sharing	2.04	1.20 – 3.45
Years IDU	1.04	1.01 – 1.07
Injecting Rx opiates	2.37	1.21 – 4.63
Injecting cocaine	2.24	1.41 – 3.54



Havens et al. Am J Public Health, 2013






Predictors of HCV Seroconversion


- Recent incarceration increased risk for HCV almost two-fold among PWID
- Those injecting for less than 1 year had the highest risk of seroconversion
- PWID who were only injecting prescription opioids were at greater risk for seroconverting
- PWID who were central in their workssharing network were at greater risk of seroconverting






- Little access to harm reduction
- Social networks
 - Drug and sharing networks in particular








- Lack of access to evidence-based substance abuse treatments
- Few HCV treatment providers in area/Lack of access to affordable treatment
- Little access to harm reduction
- H.
- Social networks
 - Drug and sharing networks in particular





- Lack of access to evidence-based substance abuse treatments
- Few HCV treatment providers in area/Lack of access to affordable treatment
- · No access to harm reduction
- Social networks
- H.
- Drug and sharing networks in particular





Next Steps

- Develop a model to improve HCV treatment access and delivery in rural areas
 - Affordable drug
 - Incorporation of evidence-based substance abuse treatment
 - Training providers on delivery of HCV treatments
 - Case management to remove barriers to care

Acknowledgements

- NIH/NIDA (R01-DA024598 and R01-DA033862) and Project Officer Peter Hartsock
- Drs. April Young, Hannah Knudsen, Michelle Lofwall, Sharon Walsh (Co-Investigators)
- Study Staff Hazard and Lexington
- Study Participants

